Tebentafusp

5 trials 4 recruiting NNeurology/Psychiatry Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

4 Recruiting

1 Completed trials

4 Sponsors

10 Countries

Phase III

Phase II/III

Phase II

Phase III: 1 Phase II/III: 1 Phase II: 3

Oversight events:

7 temporary halts 1 urgent safety measure 1 unexpected event across 1 trial

View oversight register →

Indications tested

Uveal melanoma 3 Malignant melanoma 1 Metastatic malignant melanoma 1

Sponsors using this IMP

Immunocore Limited 2 European Organisation For Research And Treatment Of Cancer 1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 Grupo Espanol Multidisciplinar De Melanoma 1

All trials

5 total

Neoadjuvant Tebentafusp in Patients with Metastatic Uveal Melanoma Recruiting

2023-509076-42-00 Phase II 2 countries Grupo Espanol Multidisciplinar De Melanoma
Hepatic radiotherapy added to standard of care for the treatment of HLA A*02:01 positive Metastatic Uveal Melanoma patients Recruiting

2024-519760-40-00 Phase II 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
EORTC 2022-MG: Treatment with tebentafusp or observation for patients with melanoma of the eye after surgery or radiation (ATOM Trial) Recruiting

2023-510333-28-00 Phase III 9 countries European Organisation For Research And Treatment Of Cancer
Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting

2022-502732-39-00 Phase II/III 7 countries Immunocore Limited
Safety and efficacy of IMCgp100 versus Investigator’s Choice in advanced uveal melanoma Ended

2024-517290-24-00 Phase II 5 countries Immunocore Limited

Showing 1–5 of 5 trials

← All drugs A–Z